Boehringer Ingelheim’s nintedanib has been designated a Promising Innovative Medicine for the treatment of malignant pleural mesothelioma (MPM) by the UK Medicine and Healthcare Products Regulatory Agency.
The 2018 Clinical Researcher of the Year—the Americas competition is well underway. Hundreds of competitors have completed Stage 1, a multiple-choice questionnaire testing knowledge of Good Clinical Practice; and Stage 2 has been implemented.
Cost regulators for NHS funded therapies in England and Wales have now published final draft guidance approving GlaxoSmithKline’s gene therapy Strimvelis for an ultra-rare immune deficiency condition commonly referred to as bubble baby syndrome.
Regulators on both sides of the Atlantic are now reviewing GW Pharmaceuticals’ cannabinoid Epidiolex as a potential treatment for seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome.